N/A
Completed N=395
Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Use Disorder
Opiate Antagonist Overdose · Opioid-Related Disorders
Source: ClinicalTrials.gov NCT02669901 ↗
Enrolled (actual)
395
Serious AEs
0.0%
Results posted
Aug 2024
Primary outcomePrimary: To Measure the Association of Take-home Naloxone With Overdose Reversals Performed by Patients With Opioid Use Disorder Enrolled in an Opioid Treatment Program — 73; 263 Participants
Summary
The purpose of this pilot-study is to to distribute naloxone auto-injector in a "Universal Precaution" manner to patients with opioid substance use disorder. The objectives are to decrease the number of fatal and nonfatal overdose deaths, to examine and understand the risk factors for serious opioid toxicity and overdose, and to evaluate the unintentional opioid overdose risk utilizing an evidence-based screening questionnaire.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY To Measure the Association of Take-home Naloxone With Overdose Reversals Performed by Patients With Opioid Use Disorder Enrolled in an Opioid Treatment Program |
73; 263 | — |
Eligibility Criteria
Inclusion Criteria
- All patients treated with methadone, naltrexone or buprenorphine as medication assisted treatment at the UNM Addiction and Substance Abuse Program (UNM ASAP) aged 18 or older
Exclusion Criteria
- Subjects who are allergic to naloxone and its inactive ingredients. Inactive ingredients include buffering agents.
- Subjects younger than 18.
- Subjects not being treated at UNM ASAP.
Data sourced from ClinicalTrials.gov (NCT02669901). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.